The Injury-Recovery Peptide Stack: What the Evidence Actually Supports, Compound by Compound

BPC-157, TB-500, and GHK-Cu are each being studied for distinct roles in tissue repair, angiogenesis, actin-mediated cell migration, and copper delivery respectively. Human evidence remains limited across all three: only BPC-157 has a registered Phase 2 trial underway. Stacking them is mechanistically plausible but untested in human subjects. None holds an FDA-approved indication.

Open a peptide-stacking guide online and you’ll usually find the same three vials on the same fridge shelf: BPC-157, TB-500, GHK-Cu. Same syringe. Same routine. Sold as a single recovery stack, like three interchangeable tools doing the same job.

They aren’t. One targets new blood vessel growth. One targets the skeleton of the cell, the scaffolding that lets it move and divide. One delivers copper to a wound. Different jobs, different molecules, different evidence, and stacking them together doesn’t make the evidence add up any faster than it already has.

Here’s what the human evidence on each one actually looks like, one at a time.

What does tissue repair actually require at the cellular level?

Cut a tendon, and the body runs the same basic program every time, at the cellular level. Blood vessels have to grow into the injury site to bring oxygen and nutrients in. That’s called angiogenesis. Cells have to migrate to the wound and physically rebuild it, and that migration depends on actin, the protein scaffolding inside every cell that lets it change shape and move. The whole process needs raw materials too, including trace minerals like copper, which feed the enzymes doing the rebuilding.

Three peptides, three different points in that chain. BPC-157 is studied mostly for the first piece, new blood vessels and nitric oxide signalling. TB-500, or whatever molecule is actually being sold under that name, is studied for the actin piece. GHK-Cu delivers the third, copper, to the site.

That’s the pitch for stacking them: hit three different steps in one repair cascade, and get more repair than any one peptide alone would give you. It’s a reasonable hypothesis. It is also, so far, untested in a human body.

BPC-157: the compound with a Phase 2 trial behind it

Start with the one that’s furthest along, because it’s also the one that gets the closest read here to a fair shake.

A randomised, double-blind, placebo-controlled Phase 2 trial, registered as NCT07437547, is testing BPC-157 against acute hamstring strain. It’s the first controlled human trial to point BPC-157 directly at an injury-recovery outcome, not a stomach ulcer, not a general safety panel. Running a trial like that costs money, years, and regulatory sign-off. Somebody decided BPC-157 was worth that bet.

That’s real. It is not, yet, proof. Before this trial, the entire registered controlled human record for BPC-157 was thin.

One Phase 1 trial, registered in 2015 as NCT02637284, sponsored by a company called PharmaCotherapia. One 2025 safety pilot testing IV infusion, with two participants. Two people. Not two hundred. Two.

The chain from rat to human runs through a single needle so far. One trial measured whether BPC-157 was safe to infuse. Two participants told researchers it didn’t obviously hurt them. Nothing in that record measured whether a hamstring strain recovered any faster.

There’s a genuine scientific argument underway too, and it’s worth sitting with instead of glossing over: BPC-157’s core mechanism, growing new blood vessels, is the same mechanism a tumour needs to grow. A 2025 published exchange in the journal Pharmaceuticals argues about exactly this, whether that angiogenic effect is a repair tool or a cancer-relevant risk. Nobody has resolved it. The honest position is that both readings stay on the table until someone runs the study that actually answers it.

So: a compound with a real trial behind it, a thin human record behind that trial, and an open mechanistic question nobody’s closed. That’s the strongest of the three peptides in this stack, and it still isn’t proven in people yet.

TB-500: which molecule are you actually buying?

Here’s where the stack starts to wobble.

TB-500 is a marketing name, not a chemical name, and it doesn’t always point at the same molecule. Thymosin beta-4, the protein it’s supposedly derived from, is a 43-residue chain that works inside the cell, holding onto actin, the scaffolding piece from the last section, so the cell can move and divide. Some vendors sell that whole 43-residue protein under the TB-500 label. Others sell a short fragment of it called LKKTETQ. Same name on the label. Different molecule in the vial.

That distinction matters because the animal evidence was built on the full protein, not the fragment. Sosne and colleagues used the intact protein on a mouse’s chemically burned cornea in 2002. Wu and colleagues loaded the intact protein into a wound-dressing scaffold in 2020. Philp and Kleinman published a 2010 review of that same animal literature. All three studies worked with the full-length protein. None of them tested the short fragment.

If you bought the fragment, the animal studies aren’t describing what’s in your vial. If you bought the full protein, you’re closer, but the underlying evidence is still animal work, a mouse cornea, a wound scaffold, a review paper. Nobody has run a controlled human trial on either version for injury recovery. The actin-polymerisation mechanism is plausible biology. It hasn’t been tested in a person yet, and depending which vial you bought, it might not even be the molecule the animal studies used.

GHK-Cu: mostly one lab, and a null result

GHK-Cu has the longest research history of the three, and also the thinnest case for doing anything beyond skin.

Almost all of that research traces back to one group, the lab of the chemist who first isolated the peptide, and human clinical data on injecting it is thin compared to the topical, skincare literature it’s better known for. That’s not automatically disqualifying. It is a fact worth knowing before you inject something whose safety case rests mostly on cream formulations tested by one team.

The one published randomised, placebo-controlled human trial of GHK-Cu skincare found it indistinguishable from placebo on every objective measurement researchers took. The only difference showed up in what people reported feeling about their own skin, not in anything a machine measured.

Injectable use has its own separate problem. A pharmacokinetics study measuring GHK after intravenous dosing in rats found it degrades fast in the bloodstream. If a compound barely survives the trip through a rat’s blood before it’s broken down, the case for it doing meaningful work systemically, reaching a torn tendon rather than sitting in a skin cream, gets weaker, not stronger.

One lab, one null RCT, and a rat pharmacokinetics paper that isn’t encouraging for the injectable use case. That’s the evidence underneath the third vial on the shelf.

Does stacking these peptides do more than using one alone?

Lifters and combat-sport athletes talk about running these three together the way people talk about a supplement stack, anecdotally, forum threads and gym-bag routines, not clinical data. That’s a real pattern of use. It isn’t evidence of anything working.

The mechanistic case for stacking sounds tidy on paper: hit angiogenesis, hit actin, hit copper delivery, cover three points in the repair chain instead of one. The mechanisms genuinely are different, that part checks out. Different pathways don’t automatically mean an additive or synergistic effect once you’re inside an actual injured tendon. Nobody has run that trial. Not in animals, not in humans, not for any combination of these three.

Three peptides in one stack, and exactly one of them has a Phase 2 trial behind it. The other two don’t have a solo human trial, let alone a combination one. That math isn’t subtle.

The synergy story is the kind of claim that sounds like pharmacology and functions like marketing: distinct targets, described with real biology, standing in for a test that was never run.

What the regulatory status does and doesn’t tell you

No FDA-approved human indication exists for any of these three peptides. That single fact gets read two opposite ways online. Either it means the compound is dangerous and being hidden from you, or it means the FDA just hasn’t caught up to the science yet. Both readings do more work than the fact itself supports.

What regulatory status actually tells you is narrower. Nobody has submitted, or completed, the kind of trial package that earns approval for human use. It doesn’t tell you the compound is unsafe. It doesn’t tell you it’s effective and being suppressed. It tells you the formal evidence bar hasn’t been cleared, for reasons that could be cost, could be trial design, could be genuine safety questions still open.

That’s a smaller, less satisfying answer than either camp online wants. It’s also the accurate one.

How to read this evidence without fooling yourself

Three peptides. Three different jobs in the body. Three completely different amounts of human evidence behind them.

BPC-157 has a real Phase 2 trial running and a genuinely open safety question about its own core mechanism. TB-500 has a labelling problem before it even gets to an evidence problem, since the animal data was built on a molecule some vendors aren’t even selling. GHK-Cu has decades of research from essentially one source and a null result the one time anyone ran a proper placebo-controlled human trial.

All three of those can be true at once, about three different peptides sold as if they were interchangeable pieces of the same stack. They aren’t interchangeable. Reading the evidence honestly means grading each one on its own record, not borrowing the strongest peptide’s credibility to cover for the weaker two.